Endo International PLC Financials

Endo International Stock Summary

Endo International competes with BCE, Arch Capital, Franklin Wireless, Weyco, and Assurant. Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. Endo International operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NMS Exchange. It employs 3103 people.

Endo International Key Financial Ratios

Generally speaking, Endo International's financial ratios allow both analysts and investors to convert raw data from Endo International's financial statements into concise, actionable information that can be used to evaluate the performance of Endo International over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Endo International PLC reports annually and quarterly.

Endo Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Endo International's current stock value. Our valuation model uses many indicators to compare Endo International value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Endo International competition to find correlations between indicators driving Endo International's intrinsic value. More Info.Endo International PLC is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies reporting about  730.00  of Return On Asset per Return On Equity. Comparative valuation analysis is a catch-all model that can be used if you cannot value Endo International by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Endo International's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Endo International's earnings, one of the primary drivers of an investment's value.

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Endo International PLC information on this page should be used as a complementary analysis to other Endo International's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

If you are still planning to invest in Endo International PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Endo International's history and understand the potential risks before investing.